Announced Phase 3 STRIVE-ON Safety Trial Met Primary Endpoint and Provided Clinical Benefit Compared ... and a decrease in our interest income of $0.2 million, offset in part by a $0.4 million ...
Vincent Gaynor remembers, almost to the minute, when he realized his part in birthing the breakthrough gene therapy Zolgensma ...
Announced Phase 3 STRIVE-ON Safety Trial Met Primary Endpoint and Provided Clinical Benefit Compared to Orally Administered Nimodipine; New Drug Application (NDA) Submission Anticipated First Half of ...
Update on extraintestinal pathogenic E. coli vaccine phase 3 clinical studyIndependent interim analysis of the E.mbrace phase 3 study finds that ...
8d
Reports fourth quarter revenues of $1.0 billion, GAAP net loss of $(1.1) billion and GAAP EPS of $(2.91); loss includes approximately $0.2 billion of non-cash charges related to manufacturing resizing ...
A scheduled review of the E.mbrace phase 3 study (clinical trial identifier: NCT04899336) conducted by an independent data monitoring committee (IDMC) determined that Sanofi and Johnson & Johnson’s ...
An NIH announcement Friday cutting billions in biomedical research, a federal funding review and DEI prohibitions have left ...
Ryan Finley explains why the IRS’s recent advice memorandum on periodic adjustments may signal a significant change in ...
Q4 2024 Earnings Call Transcript February 13, 2025 Vanda Pharmaceuticals Inc. beats earnings expectations. Reported EPS is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback